Literature DB >> 12397132

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis.

G Giovannoni, F E Munschauer, F Deisenhammer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12397132      PMCID： PMC1738139          DOI： 10.1136/jnnp.73.5.465

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  15 in total

Review 1.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Watching the gorilla and questioning delivery dogma.

Authors:  Thomas J Anchordoquy; Dmitri Simberg
Journal:  J Control Release       Date:  2017-07-14       Impact factor: 9.776

3.  Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy.

Authors:  R Lanzillo; G Orefice; A Prinster; G Ventrella; R Liuzzi; V Scarano; C Florio; G Vacca; A Brunetti; B Alfano; V Brescia Morra; V Bonavita
Journal:  Neurol Sci       Date:  2011-02-10       Impact factor: 3.307

4.  Development of a transgenic mouse model immune tolerant for human interferon Beta.

Authors:  Suzanne Hermeling; Wim Jiskoot; Daan Crommelin; Claus Bornaes; Huub Schellekens
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

5.  Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.

Authors:  Francesco Patti; Ester Reggio; Filippo Palermo; Teresa Fiorilla; Guido Politi; Alessandra Nicoletti; Arturo Reggio
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

6.  Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients.

Authors:  Marta Garcia-Montojo; Virginia De Las Heras; Manuel Bartolome; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

7.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

8.  MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.

Authors:  Andrew Pachner; Kavitha Narayan; Nicholson Price; Marie Hurd; Donna Dail
Journal:  Mol Diagn       Date:  2003

Review 9.  Optimising MS disease-modifying therapies: antibodies in perspective.

Authors:  Gavin Giovannoni
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 10.  Development of interferon beta-neutralising antibodies in multiple sclerosis--a systematic review and meta-analysis.

Authors:  Karthik Govindappa; Jean Sathish; Kevin Park; Jamie Kirkham; Munir Pirmohamed
Journal:  Eur J Clin Pharmacol       Date:  2015-08-14       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.